Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Winn

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Lupus Science & Medicine|November 15, 2014
Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurementsChaim Putterman, Richard Furie, Rosalind Ramsey-Goldman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 18, 2015
Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus ErythematosusCynthia Aranow, Diane L Kamen, Maria Dall'Era, et al.
Rheumatology (Oxford, England)|April 13, 2025
Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 U.S. rheumatology clinicsJasvinder A Singh, Larry R Hearld, Seth Eisen, et al.
The Lancet. Rheumatology|September 20, 2025
Patient outcomes from implementing a shared decision-making aid for systemic lupus erythematosus: a prospective implementation studyJasvinder A Singh, Larry R Hearld, Seth Eisen, et al.
Arthritis and Rheumatism|June 3, 2008
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritisKenneth G Saag, Gim Gee Teng, Nivedita M Patkar, et al.
Elife|May 16, 2019
IFNγ induces epigenetic programming of human T-bet<sup>hi</sup> B cells and promotes TLR7/8 and IL-21 induced differentiationEsther Zumaquero, Sara L Stone, Christopher D Scharer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 6, 2020
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus NephritisYemil Atisha-Fregoso, Susan Malkiel, Kristina M Harris, et al.
Plos Medicine|May 9, 2019
Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trialJasvinder A Singh, Liana Fraenkel, Candace Green, et al.
Arthritis Care & Research|April 5, 2012
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisJasvinder A Singh, Daniel E Furst, Aseem Bharat, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 10, 2020
Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus CohortMurray B Urowitz, Dafna D Gladman, Vernon Farewell, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Lupus Science & Medicine|November 15, 2014
Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurementsChaim Putterman, Richard Furie, Rosalind Ramsey-Goldman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 18, 2015
Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus ErythematosusCynthia Aranow, Diane L Kamen, Maria Dall'Era, et al.
Rheumatology (Oxford, England)|April 13, 2025
Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 U.S. rheumatology clinicsJasvinder A Singh, Larry R Hearld, Seth Eisen, et al.
The Lancet. Rheumatology|September 20, 2025
Patient outcomes from implementing a shared decision-making aid for systemic lupus erythematosus: a prospective implementation studyJasvinder A Singh, Larry R Hearld, Seth Eisen, et al.
Arthritis and Rheumatism|June 3, 2008
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritisKenneth G Saag, Gim Gee Teng, Nivedita M Patkar, et al.
Elife|May 16, 2019
IFNγ induces epigenetic programming of human T-bet<sup>hi</sup> B cells and promotes TLR7/8 and IL-21 induced differentiationEsther Zumaquero, Sara L Stone, Christopher D Scharer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 6, 2020
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus NephritisYemil Atisha-Fregoso, Susan Malkiel, Kristina M Harris, et al.
Plos Medicine|May 9, 2019
Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trialJasvinder A Singh, Liana Fraenkel, Candace Green, et al.
Arthritis Care & Research|April 5, 2012
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisJasvinder A Singh, Daniel E Furst, Aseem Bharat, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 10, 2020
Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus CohortMurray B Urowitz, Dafna D Gladman, Vernon Farewell, et al.
Pageof 8